United States: TotalEnergies to Acquire SunPower’s Commercial & Industrial Solar Business
Enabling TotalEnergies to expand reach in the U.S. B2B solar distributed generation; SunPower to focus…
Enabling TotalEnergies to expand reach in the U.S. B2B solar distributed generation; SunPower to focus…
Akbank, and Bank Leumi are latest lenders to build lending strategies with advanced prescriptive analytics…
AI/ML-based network planning, optimization, and modelling solution to deliver mobile network with the highest revenue…
FDA accepts Dupixent® (dupilumab) for Priority Review in children aged 6 months to 5 years…
February 10, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology…
BOSTON and TEL-AVIV, Israel, Feb. 10, 2022 (GLOBE NEWSWIRE) — Quris, an artificial intelligence (AI)…
Nominations are Open Now, With Projects and Transactions from 11 Top U.S. Markets Eligible for…
FORT COLLINS, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) — Statera Biopharma, Inc. (NASDAQ: STAB) (the…
Achieved $21.3 million revenue driven by a recovery in IXINITY sales Treosulfan NDA resubmission expected…
– Podium presentation at Association for Research in Otolaryngology Annual MidWinter Meeting highlighting DB-OTO dose-ranging…
TORONTO, Feb. 09, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTCMKTS:…
The Company has also Executed a Share Purchase Agreement to Acquire up to 34% of…
AUSTIN, TX and DURHAM, NC, Feb. 09, 2022 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (Shattuck)…
SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced…
FOURTH QUARTER IN BRIEF In 2021, we made substantial progress in our projects to address…
Monthly information regarding the total number of voting rights andtotal number of shares of the…
SEATTLE, Feb. 09, 2022 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company…
PHILADELPHIA, Feb. 09, 2022 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company…
Precomplexing NK cells with Innate Cell Engagers (ICE® molecules) results in a CAR-like NK cell…
Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end…